Watching Early Cervical Lesions Without Immediate Treatment in Young Women
Follows women aged 18 to 39 with CIN2, a precancerous cervical change, without treatment.
Plain-language title generated from the registry record
Registry title: Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN
Key facts
- Where
- Bordeaux, FranceSee the site
Where in France
- CHU BordeauxBordeaux, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT04057924
- Record updated
- 10 February 2025
- Original description
This study proposes to describe and evaluate the rate of spontaneous regression of CIN2 at 2 year of follow up in women between 18 and 39 year old. This follow-up is proposed as an alternative to the treatment of reference (conization) with a possible extension to 4 yearsRead full original descriptionShow less
Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN
This study proposes to describe and evaluate the rate of spontaneous regression of CIN2 at 2 year of follow up in women between 18 and 39 year old. This follow-up is proposed as an alternative to the treatment of reference (conization) with a possible extension to 4 years
Inclusion: CIN2 confirmed by biopsy, age between 18 and 39 years,; satisfactory colposcopy identifying the junction and the lesion,; affiliated person or beneficiary of a social security scheme,; having given their oral agreement and authorization to the processing of their data.
Exclusion: long-term treatment with corticosteroids or immunosuppressants, placement under safeguard of justice,; history of conization,; atypical or atypical glandular cells or cancer incidentally discovered during smear,; active systemic infection requiring treatment, history of HIV infection, congenital or acquired immunodepression,; Pregnancy in progress,; prophylactic vaccination against HPV,; non-compliance with protocol requirements, in particular a supposed lack of compliance with long-term follow-up.